MELISSA MCELHENNEY: Open Payments
NPI 1508403429 · MERIDIAN, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,024 in 45 payments from 11 companies in 2025. Trend: 2023 $626 · 2024 $873 · 2025 $1,024
Food & beverage: $1,024
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 10 | $200 |
| Amgen Inc. | 3 | $149 |
| ABBVIE INC. | 12 | $138 |
| Otsuka America Pharmaceutical, Inc. | 1 | $125 |
| Lundbeck LLC | 3 | $100 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $100 |
| Corcept Therapeutics | 3 | $59 |
| Lilly USA, LLC | 3 | $57 |
| PFIZER INC. | 2 | $42 |
| AstraZeneca Pharmaceuticals LP | 2 | $35 |
Products named: REXULTI, EVENITY, Ozempic, QULIPTA, Kerendia, Korlym, NURTEC ODT, FARXIGA.
Industry payments across MS — which companies pay providers there.
